ArticleFrontiers in immunology2026
CD14
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Scar-associated macrophages (SAMs), defined by triggering receptor expressed on myeloid cells 2 (TREM2) and/or glycoprotein-NMB (GPNMB) expression, have been implicated in lung fibrosis. This study investigated the characteristics and functional roles of SAMs in lung tissues from patients with systemic sclerosis-interstitial lung disease (SSc-ILD) and healthy controls (HCs). Methods: SAM-related transcriptional profiles of lung tissues from patients with SSc-ILD and HCs were analyzed using single-cell RNA sequencing (scRNA-seq). Immunofluorescence staining of lung tissues was performed to detect CD68-positive SAMs expressing TREM2 or CCL2. Monocytes from patients with SSc-ILD and HCs were differentiated with granulocyte-macrophage colony-stimulating factor (GM-CSF) or M-CSF. The population of TREM2- and GPNMB-expressing cells was assessed by flow cytometry, and the levels of CCL2 and TGF-β1 in culture supernatants were measured in an ELISA. The fibrotic effects of macrophages on fibroblasts were examined in co-cultures. TREM2 inhibition was used to determine functional relevance. Results: scRNA-seq revealed the expansion of TREM2 macrophages highly expressing SAM-associated genes in the lower lung lobes of SSc-ILD patients. Immunofluorescence showed increased numbers of CD68 Discussion: Our study identified a GM-CSF-TREM2-TGF-β1 axis driving monocytes-derived profibrotic macrophage-fibroblast crosstalk in SSc-ILD. It also showed that, in the lungs of SSc-ILD patients, CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.